CoChat
Cited by 227

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

Open access
Piao, Y., Liang, J., Holmes, L., Zurita, A. J., Henry, V., Heymach, J. V., de Groot, J. F. · 2012 · Neuro-Oncology

Abstract

Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis. Inhibiting the VEGF-VEGF receptor (R) signal transduction pathway in glioblastoma has recently been shown to delay progression, but the relative benefit and mechanisms of response and failure of anti-VEGF therapy and VEGFR inhibitors are not well understood. The purpose of our study was to evaluate the relative effectiveness of VEGF sequestration and/or VEGFR inhibition on orthotopic tumor growth and the mechanism(s) of treatment resistance. We evaluated, not only, the effects of anti-VEGF therapy (bevacizumab), anti-VEGFR therapy (sunitinib), and the combination on the survival of mice bearing orthotopic gliomas, but also the differential effects of the treatments on tumor vascularity, cellular proliferation, mesenchymal and stem cell markers, and myeloid cell infiltration using flow cytometry and immunohistochemistry. Bevacizumab significantly prolonged survival compared with the control or sunitinib alone. Both antiangiogenic agents initially reduced infiltration of macrophages and tumor vascularity. However, multitargeted VEGFR inhibition, but not VEGF sequestration, rapidly created a vascular gradient and more rapidly induced tumor hypoxia. Re-infiltration of macrophages was associated with the induction of hypoxia. Combination treatment with bevacizumab and sunitinib improved animal survival compared with bevacizumab therapy alone. However, at the time of tumor progression, a significant increase in CD11b(+)/Gr1(+) granulocyte infiltration was observed, and tumors developed aggressive mesenchymal features and increased stem cell marker expression. Collectively, our results demonstrate a more prolonged decrease in tumor vascularity with bevacizumab than with sunitinib, associated with a delay in the development of hypoxia and sustained reduction of infiltrated myeloid cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nos158

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • “In the early phases of antiangiogenic therapy, tumor oxygenation improves through the process of vascular normalization.(7) Corresponding Author: John de Groot, Unit 431, Department of”
    Background
  • Modes of resistance to anti-angiogenic therapy

    Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×

    “Although “tumor escape” from anti-VEGF therapy involves activation of other growth factors important for angiogenesis, laboratory data suggest that bone marrow–derived cells may play a critical role in tumor escape from antiangiogenic therapy.(5,6) In the early phases of antiangiogenic therapy, tumor oxygenation impro…”
    Background
  • The role of myeloid cells in the promotion of tumour angiogenesis

    Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 1×

    “Myeloid cells, such as macrophages and neutrophils, are known to promote tumor proliferation, angiogenesis, and invasion via secretion of multiple growth factors, such as matrix metalloproteinases, interleukin-6, and interleukin-8.(21) A decrease in infiltrated myeloid cells may indirectly decrease glioma proliferatio…”
    Background
  • Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

    Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 2×

    “In particular, we were interested in exploring the recruitment of CD11b+/Gr1+ cells, given their role in mediating refractoriness to anti-VEGF therapy in other tumor models.(9) Figure 5A shows the flow cytometry plots for CD11b+/F4/80– cells with pseudocoloring of Gr1+ cells from representative samples in the differen…”
    Background
  • HIF2α cooperates with RAS to promote lung tumorigenesis in mice

    Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141

    Self-citation

Cited by

See all 227

Metadata

Authors
Piao, Y., Liang, J., Holmes, L., Zurita, A. J., Henry, V., Heymach, J. V., & de Groot, J. F.
Venue
Neuro-Oncology
Published
2012-09-10
Volume
14
Issue
11
Pages
1379-1392
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2159948826
Cited by
227
References
5
FWCI
6.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.